Could you be 1 of the estimated 3300 patients in the US with the gene causing SORD Deficiency? You may have been diagnosed with CMT2, or distal hereditary motor neuropathy (dHMN). Join us as we learn more about SORD Deficiency and an investigational NEW Treatment with Shoshana Shendelman, Founder and CEO of Applied Therapeutics.
Webinar Recording: Why CMT Biomarkers Can’t Wait Thank you to everyone who joined HNF’s live...
With gratitude and respect: a note to the CMT community from NMD Pharma Dear members of the CMT...
Muscular Dystrophy Association’s Legacy Awards Honor Innovators in Clinical and Scientific...
Webinar Announcement: Biomarkers Can’t Wait – Accelerating the Path to CMT Treatments Biomarkers...
HNF Partners with MDA for CMT Series The Hereditary Neuropathy Foundation (HNF) was honored to...
Join us Saturday, October 4th from 12pm – 8pm October 4, 2025
The Nerve to Cure
CMT Social + Science Day with Evening Fundraiser Dinner
Big News for the CMT-SORD Community Updates from HNF’s TRIAD Partner, Applied Therapeutics In a...
6,000+ Strong Across 72 Countries — 2025 GRIN is Changing the Game for CMT Research! We’re...
A New CMT Treatment Is One Step Closer Augustine Therapeutics Begins Phase I Trial of AGT‑100216...
Mark your calendars for April 24–26, 2025, because the Nashville CMT Summit is bringing the...
0 Comments